Gambaran Perilaku Makan pada Mahasiswi Fakultas Kesehatan Masyarakat Universitas Sam Ratulangi

Pada masairemaja perubahan perilaku makan dapat terjadi berupa perilaku makan berisiko dan perilaku makan tidak berisiko. Perilaku makan berisiko adalah kebiasaan makan dimana baik secara kualitas maupun kuantitas tidak terpenuhi, sehingga akan berisiko pada gangguan makan. Perilaku makan tidak berisiko dimana kebutuhan gizi terpehuni baik kualitas maupun kuantitas. Tujuan penelitian yaitu untuk mengetahui gambaran perilaku makan pada mahasisiwi Fakultas Kesehatan Masyarakat Universitas Sam Ratulangi. Penelitian iniimerupakan penelitian kuantitatif dengan desain studi survei deskriptif, dilaksanakan bulan Februari-September 2021 di Fakultas Kesehatan Masyarakat Universitas Sam Ratulangi dengan jumlah sampel sebanyak 134 responden yang diambil melalui teknik sampling jenuh. Instrumen yang digunakan kuesioner EatingiAttitudes Test-26 (EAT-26) untuk mengukur gejala dan sifat mengenai perilaku makan, dalam bentuk google form. Analisis dataiyang digunakan analisis univariat. Hasil penelitianimenunjukkan mahasiswi yang memiliki perilaku makan tidak berisiko sebesar 61,9% dan mahasiswi yang memiliki perilaku makan berisiko sebesar 38,1%. Kata Kunci: Perilaku Makan, Mahasiswi ABSTRACTIn adolescence, changes in eating behavior can occur in the form of risky eating behavior and non-risky eating behavior. Risky eating behavior is eating habits where both quality and quantity are not met, so it will be at risk for eating disorders. Eating behavior is not at risk where nutritional needs are met both in quality and quantity. The purpose of the study was to describe the eating behavior of students from the Faculty of Public Health Sam Ratulangi University. This research is a quantitative study with a descriptive survey study design, carried out in February-September 2021 at the Faculty of Public Health Sam Ratulangi University with a total sample of 134 respondents taken through the sampling jenuh technique. The instrument used was the Eating AttitudesiTest-26 (EAT-26) questionnaire to measure symptoms and traits regarding eating behavior, in the form of a google form. Data analysis used univariate analysis. The results showed that female students who had no-risk eating behavior were 61.9% and female students who had risk-eating behavior were 38.1%. Keywords: Eating Behaviors, Female StudentsÂ

Kehidupan Sosial-Ekonomi Masyarakat Transmigrasi di Kelurahan Bangun Jaya Tahun 1986-2012

This study aims to determine the development of the social and economic life of transmigrant communities in A Widodo village Tugumulyo District in 1980-2017. The method that researchers use is descriptive qualitative method. Data collection techniques in research using interview techniques, observation, and documentation. Technical analysis of data with a step triangulation. Based on the results of research and discussion, it is known that the socio-economic life of the A Widodo village in the Tugumulyo District in 1980-2017 has changed from the beginning of the A Widodo feda in 1937 to the present. This changed can be seen from the field of education. Ranging from opening a business, trading, raising livestock, to fish farming and other, other in the fields of education and economic, also seen in the form of social and religious interactin, where individuals interact with each other and help each other help each other, they repect each other’s religions in the village of A Widodo, namely Islam, Protestantism, Catholic Christianity, Hinduism, they do not mock one another or insult religion. Will determine a person’s social status, the higher the level of education the easier it is to find work and the more respected by the surrounding community

Jet-loop reactor with cross-flow ultrafiltration membrane system for treatment of olive mill wastewater

ABSTRACT: Olive oil extraction is one of the ancient agricultural industries all over the Mediterranean area and even today it is of fundamental economic importance for many industries found over the whole Mediterranean. However, this industry generates large amounts of olive mill wastewater (OMW) and due to its physicochemical characteristics it causes severe environmental concerns and management problems in the Mediterranean area, which is facing water scarcity. Technologies to reuse this wastewater will have a high impact at the economic and environmental level. The work presented aims to improve the use of jet-loop reactors technology for the aerobic biotreatment of OMW. A jet-loop reactor (100 L) coupled with an ultrafiltration (UF) membrane (MBR) system (JACTO.MBR_100 L) were tested for the influence of hydraulic parameters on OMW degradation and scale-up to 1,000 L. Chemical oxygen demand and total phenols (TP) decreased notably (up to 85% and 80% removal efficiency, respectively) after the biological treatment. The treated OMW (UF permeate) was evaluated as a source for irrigation and its impact on the soil and plant growth and their quality parameters.info:eu-repo/semantics/publishedVersio

Bringing onco‐innovation to Europe’s healthcare systems. The potential of biomarker testing, real world evidence, tumour agnostic therapies to empower personalised medicine

Rapid and continuing advances in biomarker testing are not being matched by uptake in health systems, and this is hampering both patient care and innovation. It also risks costing health systems the opportunity to make their services more efficient and, over time, more economical. The potential that genomics has brought to biomarker testing in diagnosis, prediction and research is being realised, pre‐eminently in many cancers, but also in an ever‐wider range of conditions— notably BRCA1/2 testing in ovarian, breast, pancreatic and prostate cancers. Nevertheless, the implementation of genetic testing in clinical routine setting is still challenging. Development is impeded by country‐related heterogeneity, data deficiencies, and lack of policy alignment on standards, approval—and the role of real‐world evidence in the process—and reimbursement. The acute nature of the problem is compellingly illustrated by the particular challenges facing the development and use of tumour agnostic therapies, where the gaps in preparedness for taking advantage of this innovative approach to cancer therapy are sharply exposed. Europe should already have in place a guarantee of universal access to a minimum suite of biomarker tests and should be planning for an optimum testing scenario with a wider range of biomarker tests integrated into a more sophisticated health system articulated around personalised medicine. Improving healthcare and winning advantages for Europe’s industrial competitiveness and innovation require an appropriate policy framework—starting with an update to outdated recommendations. We show herein the main issues and proposals that emerged during the previous advisory boards organised by the European Alliance for Personalized Medicine which mainly focus on possible scenarios of harmonisation of both oncogenetic testing and management of cancer patients

Bringing onco-innovation to Europe’s healthcare systems: the potential of biomarker testing, real world evidence, tumour agnostic therapies to empower personalised medicine

International audienceRapid and continuing advances in biomarker testing are not being matched by uptake in health systems, and this is hampering both patient care and innovation. It also risks costing health systems the opportunity to make their services more efficient and, over time, more economical. The potential that genomics has brought to biomarker testing in diagnosis, prediction and research is being realised, pre-eminently in many cancers, but also in an ever-wider range of conditions—notably BRCA1/2 testing in ovarian, breast, pancreatic and prostate cancers. Nevertheless, the implementation of genetic testing in clinical routine setting is still challenging. Development is impeded by country-related heterogeneity, data deficiencies, and lack of policy alignment on standards, approval—and the role of real-world evidence in the process—and reimbursement. The acute nature of the problem is compellingly illustrated by the particular challenges facing the development and use of tumour agnostic therapies, where the gaps in preparedness for taking advantage of this innovative approach to cancer therapy are sharply exposed. Europe should already have in place a guarantee of universal access to a minimum suite of biomarker tests and should be planning for an optimum testing scenario with a wider range of biomarker tests integrated into a more sophisticated health system articulated around personalised medicine. Improving healthcare and winning advantages for Europe’s industrial competitiveness and innovation require an appropriate policy framework—starting with an update to outdated recommendations. We show herein the main issues and proposals that emerged during the previous advisory boards organised by the European Alliance for Personalized Medicine which mainly focus on possible scenarios of harmonisation of both oncogenetic testing and management of cancer patients

Bringing onco‐innovation to Europe’s healthcare systems: The potential of biomarker testing, real world evidence, tumour agnostic therapies to empower personalised medicine

Rapid and continuing advances in biomarker testing are not being matched by uptake in health systems, and this is hampering both patient care and innovation. It also risks costing health systems the opportunity to make their services more efficient and, over time, more economical. The potential that genomics has brought to biomarker testing in diagnosis, prediction and research is being realised, pre‐eminently in many cancers, but also in an ever‐wider range of conditions— notably BRCA1/2 testing in ovarian, breast, pancreatic and prostate cancers. Nevertheless, the implementation of genetic testing in clinical routine setting is still challenging. Development is impeded by country‐related heterogeneity, data deficiencies, and lack of policy alignment on standards, approval—and the role of real‐world evidence in the process—and reimbursement. The acute nature of the problem is compellingly illustrated by the particular challenges facing the development and use of tumour agnostic therapies, where the gaps in preparedness for taking advantage of this innovative approach to cancer therapy are sharply exposed. Europe should already have in place a guarantee of universal access to a minimum suite of biomarker tests and should be planning for an optimum testing scenario with a wider range of biomarker tests integrated into a more sophisticated health system articulated around personalised medicine. Improving healthcare and winning advantages for Europe’s industrial competitiveness and innovation require an appropriate policy framework—starting with an update to outdated recommendations. We show herein the main issues and proposals that emerged during the previous advisory boards organised by the European Alliance for Personalized Medicine which mainly focus on possible scenarios of harmonisation of both oncogenetic testing and management of cancer patients

Contribution to "Deliverable 4: Activity 6: Pilot Demonstrations: Pilot testing, 2nd milling campaign"

Report for Deliverable 4: Activity 6 of MEDOLICO Project - Mediterranean Cooperation in the Treatment and Valorisation of Olive Mill Wastewater, EU Programme ENPI-CBCMED I-B/2.1/09